464 related articles for article (PubMed ID: 20234341)
1. Synergistic interaction between oncolytic viruses augments tumor killing.
Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
[TBL] [Abstract][Full Text] [Related]
2. Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.
Cronin M; Le Boeuf F; Murphy C; Roy DG; Falls T; Bell JC; Tangney M
Mol Ther; 2014 Jun; 22(6):1188-1197. PubMed ID: 24569832
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
4. United virus: the oncolytic tag-team against cancer!
Le Boeuf F; Bell JC
Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia virus GLV-1h237 carrying a Walker A motif mutation of mouse Cdc6 protein enhances human breast tumor therapy in mouse xenografts.
Hofmann E; Grummt F; Szalay AA
Int J Oncol; 2011 Mar; 38(3):871-8. PubMed ID: 21249314
[TBL] [Abstract][Full Text] [Related]
7. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
[TBL] [Abstract][Full Text] [Related]
8. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
9. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
[TBL] [Abstract][Full Text] [Related]
10. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
Fu X; Rivera A; Tao L; Zhang X
Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
[TBL] [Abstract][Full Text] [Related]
12. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
14. [Vesicular stomatitis virus in the fight against cancer].
Janelle V; Poliquin L; Lamarre A
Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
[TBL] [Abstract][Full Text] [Related]
15. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
16. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
17. A tool with many applications: vesicular stomatitis virus in research and medicine.
Munis AM; Bentley EM; Takeuchi Y
Expert Opin Biol Ther; 2020 Oct; 20(10):1187-1201. PubMed ID: 32602788
[TBL] [Abstract][Full Text] [Related]
18. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
19. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.
Jenner AL; Cassidy T; Belaid K; Bourgeois-Daigneault MC; Craig M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608375
[TBL] [Abstract][Full Text] [Related]
20. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]